<DOC>
	<DOCNO>NCT00092924</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TRM-1 subject relapse refractory non-small cell lung cancer .</brief_summary>
	<brief_title>Study TRM-1 ( TRAIL-R1 Monoclonal Antibody ) Subjects With Relapsed Refractory Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Primary Relapsed refractory histologically cytologically confirm Stage IIIB , IV , recurrent NSCLC Previously treat fail respond standard therapy progress standard therapy 18 year age old Primary Received nonFDA approve investigational agent within last 4 week . Previous cancer therapy ( chemotherapy , hormonal therapy , monoclonal antibody radiation therapy ) within last 3 week , 8 week fully human humanize monoclonal antibody Infection require antibiotic hospitalization within last 2 week HIV , HepatitisB , HepatitisC Pregnant breastfeed woman Major surgery within last 4 week History cancer within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>